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1. Introduction 
A few words about mitochondria …. 
Mitochondria are active intracellular structures that collide, divide, and fuse with other 
mitochondria. Mitochondria exist as branched-chain reticulum networks, but can also exist 
as punctuated structures. Their distribution within the cells is quite diverse, is regulated by 
the interactions with the cytoskeleton and maintained by the balance between mitochondrial 
fusion and fission.  
Mitochondria play crucial physiological functions that underlie the distortions of fragile 
balance between health and disease. In recent years, the role of mitochondria has gained 
much interest in the field of diabetic pathology since mitochondrial abnormalities were 
found in insulin resistance and in both types of diabetes. 
A few words about hyperglycaemia and diabetes…. 
Hyperglycaemia, resulting from uncontrolled regulation of glucose metabolism, is widely 
recognized as the causal link between diabetes and diabetic complications. Diabetes mellitus 
has been classified into two forms. Type 1 diabetes, which accounts for about 10% of all 
cases of diabetes, is caused by autoimmune destruction of pancreatic ǃ-cells that implies 
insulin deficiency. Type 2 diabetes, the more prevalent form of diabetes, is considered a 
heterogeneous disease due to the multiplicity of factors that cause the observed phenotype. 
It results from the combination of insulin resistance and/or a ǃ-cell secretory defects. The 
explosive increase in the prevalence of type 2 diabetes is predicted in the nearest future. It is 
considered that about 220 millions people all over the world may suffer from the condition, 
and an equal number is thought to be “prediabetic”, having early symptoms and not yet full 
manifestation of the disease. 
A few words about impact of hyperglycaemia on mitochondria ….. 
Hyperglycaemia has been indicated as one of the main causes of altered mitochondrial 
function in diabetic individuals (animals and humans). Rather huge variation in the extent of 
damage has been observed and attributed to both the type and duration of diabetes studied. 
General consensus points out to the formation of glycation products as a crucial mechanism, 
by which hyperglycaemia affects mitochondrial and cellular function in diabetes. 
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Hyperglycaemia elicits an increased ROS production, presumably to the major extent 
originating from mitochondrial respiratory chain. ROS play a central role in mediating 
various metabolic defects associated with a diabetic state. Therefore, the inhibition of ROS 
production and/or enhancement of ROS scavenging might prove to be beneficial therapies. 
Alterations in metabolic regulators and glucose-stimulated insulin secretion are also 
associated with mitochondrial dysfunction in diabetes. 
Impairments in mitochondrial function are intrinsically related to diabetes. The prevailing 
hypothesis is that hyperglycaemia-induced increase in electron transfer donors (NADH and 
FADH2) may increase electron flux through the mitochondrial electron transport chain. 
Consequently, the ATP/ADP ratio and hyperpolarisation of the mitochondrial membrane 
(electrochemical potential difference) also become increased. This high electrochemical 
potential difference generated by the proton gradient leads to partial inhibition of the 
electron transport in the complex III, resulting in the augmented electron flow towards 
coenzyme Q. In turn, this drives partial reduction of O2 to generate the free radical anion 
superoxide. It is accelerated reduction of coenzyme Q and generation of ROS that are 
believed to constitute the fundamental source for mitochondrial dysfunction that plays a 
critical role in diabetes-related metabolic disorders and tissue histopathology. 
A few words about oxidative stress….. 
Oxidative stress has been implicated as a major contributor to both the onset and the 
progression of diabetes and its associated complications. Some of the consequences of an 
oxidative environment may be the development of insulin resistance, ǃ-cell dysfunction, 
impaired glucose tolerance, and mitochondrial dysfunction, which can ultimately lead to the 
diabetic disease state. Experimental and clinical data suggest an inverse association between 
insulin sensitivity and ROS levels. Oxidative stress can arise from a number of different 
sources, like the disease state or lifestyle, including episodes of ketosis, sleep restriction, and 
excessive nutrient intake. Oxidative stress can be reduced by controlling calorie intake, 
hyperglycaemia and mitochondrial metabolism.  
It is now established that 90% of intracellular ROS are generated by mitochondria. The 
mitochondrial respiratory chain is the principal source of cellular oxygen radicals (ROS), 
such as superoxide anion radicals and hydroxyl radicals. The primary factor governing 
mitochondrial ROS generation is the redox state of the respiratory chain. If the membrane 
potential across the inner mitochondrial membrane rises above a certain threshold value, a 
massive stimulation of ROS generation occurs. Electrons leak mainly from the complexes I 
and III of the electron transport chain (ETC) and thereby generate incompletely reduced 
forms of oxygen. The rise in a membrane potential may occur as a consequence of 
augmented delivery of electrons to the respiratory chain, which results from either increased 
glucose or fatty acid oxidation or as a result of altered ETC stoichiometry. Consequently, an 
increased reverse electron flow occurs. Also, there is an evidence that increased cytosolic 
generation of ROS might precipitate increased mitochondrial ROS. The balance between the 
genesis of physiological mitochondrial ROS and antioxidant defenses may thus become 
disturbed, causing numerous pathological events, and finally leading to cell death.  
A few words about an interesting association between mitochondrial ATP production and ATP 
deficiency in pathology…. 
Mitochondria are the primary source of ATP production in every cell. Therefore, disruption 
of mitochondrial respiratory function is regarded as a key event in the development of 
pathologic complications due to ATP depletion in different tissues, like for instance in heart 
tissue in diabetic patients. However, no general consensus has been raised about the 
occurrence of mitochondrial defects under diabetic conditions. Evidence associating 
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diabetes with impaired mitochondrial respiratory function in the liver, heart and kidney of 
diabetic animals dates back more than 45 years. Despite this long history of research, we 
have still no comprehensive knowledge on the nature and extent of mitochondrial 
dysfunction in diabetics, as well as about the mechanisms linking this secondary metabolic 
abnormality with the primary metabolic defect in insulin and hyperglycaemia. The 
relationship between mitochondrial dysfunction and diabetic pathology has also not yet 
been defined and elucidated.  
In summary….. 
In this chapter we discuss how to possibly modulate the “vicious circle” established between 
mitochondria, oxidative stress and hyperglycaemia. The potential application of some existing 
and some new agents possessing promising anti-glycation properties to reduce glycation 
phenomenon and to increase the antioxidant defense system by targeting mitochondria is 
discussed. Moreover, this chapter outlines various mechanisms present in mitochondria that 
may lead to the development of diabetes. Intervention and therapy that alter or disrupt these 
mechanisms may serve to reduce the risk of development of this pathology. 
2. Impact of hyperglycaemia on cellular biochemistry/metabolism – overview 
of the recent achievements in the field  
Glycation and oxidative stress are two important processes known to play a key role in the 
etiopathology of complications in numerous disease processes. Oxidative stress, either via 
increasing reactive oxygen species (ROS), or by depleting the antioxidants, may modulate 
the genesis of glycated proteins in vitro, as well as in vivo.  
2.1 Hyperglycaemia – the basic knowledge on Louis Maillard’s discovery  
Glycation (non-enzymatic N-glycosylation) is an endogenous process that contributes to the 
post-translational modification of proteins. It is slow under normal physiological conditions, 
giving rise to the presence of lysine- and arginine-derived glycation adducts in cellular and 
extracellular proteins. Inside cells, the impact of glycation is countered by high turnover and 
short half-life of numerous cellular proteins. In long-lived extracellular proteins, however, 
glycation adducts accumulate with age (Sell et al., 1996). Then, some of these adducts may 
be removed by enzymatic repair mechanisms, whilst all are removed by degradation of the 
glycated proteins. Degradation of extracellular glycated proteins requires specific 
recognition by receptors, internalisation and proteolytic processing. There are specific 
receptors, AGE receptors, which fulfill this role (Thornalley, 1998).  
The Maillard reaction is named after Louis Maillard, who discovered over 80 years ago that 
some amines and reducing carbohydrates react to produce brown pigments (Ellis, 1959). The 
Maillard reaction proceeds via three major stages (early, advanced and final stage) and is 
dependent upon factors such as pH, time, temperature, as well as type and concentrations of 
reactants. Maillard reactions occur both in vivo and in vitro, and are associated with the 
chronic complications of diabetes, aging and age-related diseases (Edeas et al., 2010). The 
first step of this reaction typically involves the nucleophilic addition of a reducing sugar to a 
primary amine group (e.g. as found on a lysine or at the N-terminus of a protein). In this 
stage a reversible Schiff base is formed, which can undergo a slow irreversible 
rearrangement to form more stable Amadori product that accumulates over time (Fig. 1). 
The total amount of such accumulated products is known to be dependent on the type of 
sugar that is causing the glycation, the incubation time and sugar concentration, as well as 
the type protein that is being modified (Barnaby et al., 2011). 
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Fig. 1. General scheme of Maillard pathways in diabetic organism. 
The first product of Maillard reaction is a simple glycosylamine, which readily undergoes the 
Amadori rearrangement to produce 1-amino-1-deoxy-2-ketoses. The large body of literature 
on these reactions is due to the multitude of possible reaction pathways and products, 
including fragmentations of the carbohydrates and formation of aromatic compounds from 
cyclisation/dehydration processes (Hodge, 1955). Reducing disaccharides also undergo this 
reaction, and it is a well-documented process for the degradation of lactose during the heating 
of milk. Reducing carbohydrates such as glucose, maltose, and lactose are tautomers and are in 
equilibrium with their more reactive aldehyde forms; nonreducing carbohydrates, such as 
mannitol, sucrose and trehalose, are not subject to Maillard reactions. Although early scientists 
believed that only primary aromatic amines were capable to become glycated, subsequent 
research has shown that nearly all primary and secondary amines, both aromatic and aliphatic, 
are capable of this reaction (Wirth et al., 1998). 
Fragmentation of glucose adducts in early glycation processes establishes many parallel 
glycation pathways that lead to the subsequent formation of the so-called Advanced 
Glycation End-products (AGEs). Analogous oxidation and dehydration reactions have been 
found in glycation by other hexose and pentose derivatives. Glyoxal, methylglyoxal and 3-
deoxyglucosone (3-DG)-derived AGEs may be present in proteins glycated by glucose. 
Methylglyoxal-derived AGEs are common to proteins modified by glucose and by the 
authentic α-oxoaldehyde. Indeed, similar binding to AGE receptors has been found for these 
proteins. The formation of α-oxoaldehydes from monosaccharides, Schiff's bases and 
fructosamines suggests that AGEs may be formed at all stages of glycation (Westwood et al., 
1999). AGEs alter structure and functions of proteins. It has been shown that the formation 
of AGEs in vivo contributes to several pathophysiological impairments associated with aging 
and diabetes mellitus, such as chronic renal insufficiency, Alzheimer’s disease, nephropathy, 
neuropathy and cataract (Ravelojaona et al., 2007).  
2.2 Impact of AGEs on human organism – undesirable effects on our health  
Glycation of amino-groups on small or large cell constituents induces a number of undesirable 
effects in a plethora of age-related pathologies, overall referred to as glycation-induced health 
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hazards and including cardiovascular diseases, kidney insufficiencies, retinopathy, or effects 
of AGEs on embryonic development, as observed in diabetes-related gravidities. As such 
reactions proceed with a speed proportional to the concentrations of the interacting 
substances, hyperglycaemia is an important factor for its acceleration (Urios et al., 2007). 
It is very important to remember that Maillard products derive also from ‘‘ready made’’ 
ingested food. Table 1 shows the contents of Maillard products in some foods (expressed as 
Nε-carboxylysine), as selected from data published by Goldberg et al. (2004).  
 
Name of the selected food AGE content [U/g]* 
Bread 
Whole wheat, crust, toasted 
1.39 
Corn flakes 2.32 
Peanut Butter Chocolate 32 
Popcorn, microwave 336 
Butter 265 
Fruits: 
Apple 
Apple baked 
Banana 
 
127 
445 
87 
Vegetables: 
Broccoli, carrots, celery 
Carrots, canned 
Pepper, mushrooms 
Tomato, raw 
 
2.26 
103 
2.66 
234 
Liquids: 
Milk, whole 
Formula, infant 
Human milk, fresh 
Apple juice 
Orange juice, carton 
 
48 
486 
52 
20 
56 
Beverages: 
Coffee, instatnt 
Tea 
Cola 
 
53 
19 
65 
Condiments: 
Ketchup 
Mustard 
Vinegar sauce, white 
 
103 
29 
377 
Cheese: 
Feta 
Mozzarella 
Parmesan 
 
84 
17 
169 
Hamburger, fast food 54 
*AGE denotes N-carboxymethyllysine (CML)-like immunoreactivity, assessed by enzyme-linked 
immunosorbent assay using monoclonal antibody 4G9. 
Table 1. The content of Maillard products in the selected victuals. 
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The Maillard reaction between reducing sugars and amino acids is a common reaction in 
foods, which undergo thermal processing. Desired consequences, like the formation of 
flavor and brown color of some cooked foods, but also the destruction of essential amino 
acids and the production of anti-nutritive compounds, require to consider the relevant 
mechanisms for controlling of Maillard reaction intermediates and final products. Processes 
such as roasting, baking or frying rely on favorable effects of the Maillard reaction, such as 
color and flavor formation, whereas during drying, pasteurisation and sterilisation the 
occurrence of the Maillard reaction is unfavorable. Nutritional losses of essential amino 
acids that are involved in the reaction, as well as the formation of reaction products are 
among those unwanted effects (Jaeger et al., 2010). 
There is a limited number of studies that have been used to investigate the health effects of 
dietary Maillard neoformed compounds in humans. Some observational studies have been 
carried out to address the question of absorption, biodistribution and elimination of dietary 
Maillard Reaction Products (MRP), and to observe the associations between food exposure 
to MRPs and their in vivo levels.  
Some reports have shown that in tobacco leaves, which are dried in the presence of sugars, 
the Maillard reaction cascade leads to a formation of glycated and oxidative derivatives. 
These compounds are inhaled during the smoking, after that they are absorbed by lungs and 
conjugated with serum proteins. It was evidenced that total serum AGE level in cigarette 
smokers is significantly higher in comparison with non-smokers. However, the highest level 
of AGEs was detected in the arteries and ocular lenses in diabetic smokers (Vlassara & 
Palace, 2002). 
Furthermore, high AGE levels were observed in industrially preprocessed foods from 
animal products, like frankfurters, bacon, and powdered egg whites, compared with the 
unprocessed forms. Across all categories, exposure to higher temperature most of all raised 
the AGE content (for equal food weights). The temperature level appeared to be more 
critical than the duration. Also, microwaving increased AGE content more rapidly 
compared with conventional cooking methods (Peppa et al., 2002). Based on the above data, 
it is well evidenced that dietary glycoxidation products may constitute an important link 
between the increased consumption of animal fat and meat and the subsequent 
development of diabetic complications. However, the problem of AGEs’ presence in food is 
well known, and therefore presently scientists call to use diets containing low contents of 
these compounds undesirable for out health. 
Paradoxically, because of the metabolic demands of the brain, the human body has an 
obligatory requirement for glucose, approaching 200 g/day. The blood glucose 
concentration is tightly regulated by homeostatic regulatory systems and maintained 
between 40 mg/dl (2.2 mmol/l) and 180 mg/dl (10.0 mmol/l). Hypoglycaemia below the 
lower limit may result in coma, seizures, or even death. Hyperglycaemia, exceeding the 
upper limit, is associated with immediate glycosuria and caloric loss, as well as long-term 
consequences, like retinopathy, atherosclerosis, renal failure, etc. Under normal 
physiological conditions hyperglycaemia stimulates insulin secretion, promoting uptake of 
glucose by muscles and adipose tissue (Chiu & Taylor, 2011). 
Nevertheless, several studies suggest that some MRPs present in foods could have beneficial 
effects on human health. For instance, the melanoidins are brown Maillard polymers, which 
seem to have functional properties in food products and are also capable of inhibiting 
growth of a tumour cell line in culture (Marko et al., 2003). In addition, it was also found 
recently that a selection of foods rich in MRPs could inhibit the oxidation of LDL in vitro. 
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The high diversity of the MRPs formed in the very diverse food matrices makes it 
impossible to classify all of them as glycotoxins. It is admitted that they have different 
beneficial or detrimental biological activities. Thus, more well-controlled clinical 
experiments are needed to establish the role of the ingested MRPs, pure or added to food 
matrices, following acute or chronic exposures (Tessier & Birlouez-Aragon, 2010). 
2.3 The role of Reactive Oxygen Species (ROS) in glycation process  
Free radicals in biological materials were discovered less than 60 years ago. Soon thereafter, 
Denham Harman hypothesized that reactive oxygen radicals may be formed as by-products 
of enzymatic reactions in vivo. In 1956 he described free radicals as a Pandora’s box of evils 
that may account for gross cellular damage, mutagenesis, cancer, and, last but not the least, 
the degenerative process of biological aging (Harman, 1956). Presently, the list of cell and 
tissue disorders caused by free radicals is very long and the diseases, such as diabetes 
and/or impairments in mitochondria functions, also belong to the “victims” of ROS attack.  
Glycation and oxidative stress are closely linked, and both phenomena coincide in a vicious 
process referred to as ‘‘glycoxidation’’. In all steps of glycoxidation there is a massive 
generation of oxygen-free radicals, some of them being common with lipidic peroxidation 
pathways. Besides, glycated proteins, and especially their advanced adducts, activate 
membrane receptors, such as RAGE, and induce an intracellular oxidative stress and a pro-
inflammatory status. Glycated proteins may modulate functions of cells involved in oxidative 
metabolism and induce inappropriate responses. Finally, some oxidative products (reactive 
aldehydes such as methylglyoxal) or lipid peroxidation products (malondialdehyde) may bind 
to proteins and amplify glycoxidation generated lesions (Hunt et al., 1998). 
Recently, oxygen free radicals, antioxidant defences and the cellular redox status have been 
considered as central players in pathogenesis of diabetes. The role of glycaemic control on 
the pro-oxidant/antioxidant balance deserves special attention. Metabolic disturbances and 
oxidative stress seem to be closely related, improved glycaemic control being associated 
with a lowered pro-oxidant status (Wierusz-Wysocka et al., 1995).  
It was also evidenced that there is a relationship between oxidative stress and insulin 
resistance observed in diabetes. Hyperinsulinaemia increases the concentrations of ROS, 
which, in turn, may be responsible for the impaired intracellular insulin actions. Amongst 
ROS, hydrogen peroxide has been shown to contribute to insulin receptor signaling, and 
may play a key role in the modulation of the signalling transduction pathways regulated by 
insulin through coupled receptors. 
Consequently, the inactivation of hydrogen peroxide by catalase could represent a critical 
step for the removal of intracellular ROS in insulin-producing cells. On the other side, the 
inhibition of catalase under conditions of insulin resistance could also represent an adaptive 
response to maintain the homeostasis of intracellular hydrogen peroxide as an intermediate 
of the insulin-activated physiological processes. Overall, relationships between ROS and 
diabetes seem extremely complex (Bonnefont-Rousselot, 2002). 
A second source of ROS formation is an excessive production of AGEs, especially due to a 
hyperglycaemia-induced overproduction of methylglyoxal. AGEs are also able to produce 
oxygenated free radicals via complex biochemical mechanisms. AGEs have been shown to 
interact with their specific receptors (RAGE) and thus they induce oxidative stress, enhance 
vascular cell adhesion molecule type 1 (VCAM-1) expression, and increase endothelial 
adhesiveness for monocytes. This overproduction of AGEs appears to play a key role in the 
pathogenesis of diabetic complications. In particular, the accumulation of two AGEs 
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biomarkers, namely carboxymethyllysine and pentosidine, has been related to the severity 
of diabetic nephropathy and the so-called ’carbonyl stress’. The toxic effects of AGEs result 
from structural and functional alterations in proteins, especially the cross-linking of 
proteins, and from their interactions with RAGEs leading to the enhanced formation of 
oxygen free radicals (Miyata et al., 2001; Singh et al., 2001). 
2.4 Diabetes – a frequent disease or an epidemic?  
In 1993 the World Health Organisation (WHO) Ad Hoc Diabetes Reporting Group 
published standardized global estimates for the prevalence of diabetes and impaired 
glucose tolerance in adults, based on data from 75 communities in 32 countries. These 
estimates provided, for the first time, comparable information on the prevalence of 
abnormal glucose tolerance from many populations worldwide. However, they did not 
meet the needs of those who frequently refer to the WHO diabetes program for information 
on the number of people with diabetes in a particular country/community, nor did they 
take account of future trends in the burden of diabetes (King & Rewers, 1993). Therefore, a 
further study has been undertaken that links data from the global database collected by 
WHO with demographic estimates and projections issued by the United Nations to estimate 
the number of people with diabetes in all countries of the world at three points in time, i.e., 
the years 1995, 2000, and 2025. The results of this study suggest that for the world as a 
whole, between the years 1995 and 2025, the adult population will increase by 72%, 
prevalence of diabetes in adults will increase by 35%, and the number of people with 
diabetes will increase by 122% (Fig. 2). For the developed countries, there will be an 11% 
increase in the adult population, a 27% increase in the prevalence of adult diabetes, and a 
42% increase in the number of people with diabetes. For the developing countries, there will 
be an 82% increase in the adult population, a 48% increase in the prevalence of adult 
diabetes, and a 170% increase in the number of people with diabetes (King et al., 1998). 
 
 
Fig. 2. Global projections for the diabetes epidemic in years 2003-2025. 
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It is well known that diabetes is one of the most costly and burdensome chronic diseases of 
our time and is a condition that is increasing in epidemic proportions throughout the world. 
The prevalence of abnormal glucose tolerance in any population is of public health concern, 
since diabetes may increase disability burden and health care utilisation. 
The relationship between blood glucose concentration in diabetes and the incidence of 
disease complications was demonstrated in large epidemiological studies. Accurate 
metabolic control in diabetes is not always feasible, and therefore the issue of molecular 
mechanisms underlying the damaging effects of hyperglycaemia on body cells and tissues, 
as well as the possibilities of their pharmacological inhibition, are of the utmost importance 
in a diabetological practice and anti-diabetic treatment.  
The complications resulting from the disease are a significant cause of morbidity and 
mortality and are associated with the damage or failure of various organs such as eyes, 
kidneys, and nerves. Although the treatment of diabetes has become increasingly 
sophisticated, with over a dozen pharmacological agents available to lower blood glucose, a 
multitude of ancillary supplies and equipment available, and a clear recognition by health 
care professionals and patients that diabetes is a serious disease, the normalisation of blood 
glucose for any appreciable period of time is seldom achieved. In addition, in well-
controlled so called “intensively” treated patients, serious complications still occur, and the 
economic and personal burden of diabetes remains (Turner et al., 1999). 
Nowadays, diabetes is treated not only as a disease, but as an epidemic. However, as a 
discipline, diabetes epidemiology is relatively young. The first significant gathering of 
researches interested in diabetes epidemiology took place just in 1978. Then, in the relatively 
short span of 2 decades, epidemiology studies have had a profound impact on diabetes 
research, care and prevention. This explosion of interest and activity in the epidemiology of 
diabetes should contribute to an effective reduction in the number of patients with this 
disease.  
3. Mitochondria – the relationship between the structure and the function  
Mitochondria are multifunction organelles, which play a key role in both the proper 
functioning of the cell and normal cell death scenario (Kuznetsov & Margreiter, 2009, as 
cited in McBride et al., 2006). Their main role is the production of adenosine triphosphate 
(ATP) through metabolic processes involving tricarboxylic acid cycle (TCA) and the electron 
transport chain (ETC). Most cellular ATP is generated in the process of oxidative 
phosphorylation, which is possible thanks to the ‘sophisticated machinery’ located in the 
inner mitochondrial membrane. Mitochondria participate in the regulation of redox state 
and calcium homeostasis in cell. Cations of calcium regulate some mitochondrial processes, 
such as enzyme activity, i.e. pyruvate dehydrogenase, or metabolic rate. These organelles 
participate in biosynthesis of amino acids, vitamin cofactors, fatty acids and 
neurotransmitters (Waldbaum & Patel, 2009). Many other biochemical reactions are 
associated with the functioning of these structures, including synthesis of heme group and 
some steps of steroid synthesis. Also, a part of the processes occurring in the urea cycle take 
place there (Pinti et al. 2010). Mitochondria have critical function in the control of apoptotic 
and necrotic cell death and in most types of cells they are also a major site of reactive oxygen 
species (ROS) generation (Duchen, 2004). ROS are involved in many signaling pathways. 
Most of them are second messengers that trigger different cellular events, such as cytokine 
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secretion or activation of transcription factors, but in excess they can contribute to the 
formation of defects in mitochondria, as well as in a whole cell (Edeas et al., 2010a). 
3.1 Mitochondrial structure and biogenesis 
Mitochondria are encapsulated by two membranes, each with different structure and 
function, separated by intermembrane space, in which some important proteins involved 
in the mitochondrial bioenergetics and/or cell death are located (Fig. 3) (Duchen, 2004, 
Borutaite, 2010). The outer membrane contains porins, which make it permeable to 
molecules smaller than 5-6 kDa (Waldbaum & Patel, 2009). Compounds such as water, O2, 
CO2, and NH3 easily pass through the membrane, but hydrophilic metabolites and all 
inorganic ions in order to get over this membrane require the participation of specific 
channels and carrier proteins. Such a transport is generally based on the exchange of 
molecules, i.e. ADP is exchanged for ATP and Pi (inorganic phosphate) for OH- (Szewczyk 
& Wojtczak, 2002). The mitochondrial inner membrane contains enzymes facilitating an 
oxidative phosphorylation (OXPHOS). This complex of enzymes consists of four 
oxidoreductases involved in respiratory electron transport (Complexes I - IV) and the ATP 
synthase complex (Complex V).  
 
 
Fig. 3. Mitochondria structure and components. 
Until recently, the inner membrane has been described as a multiple infolded structure 
forming cristae and containing numerous mitochondrial proteins (Duchen, 2004). However, 
electron tomographic analyses of a variety of mitochondria (both isolated and observed in 
situ in various cell types) have provided overwhelming evidence showing the need of some 
changes in the perception of the structure of these organelles. These infoldings or rather 
invaginations are not randomly spaced in the membrane, as often considered, but resemble 
microcompartments, which face each other in the peripheral region of the membrane. The 
narrow junctions are wide enough to pass metabolites and many soluble proteins (Mannella, 
2008). However, the number of cristae junctions and the morphology of the intercristal space 
depends on the metabolic state of mitochondria (Logan, 2006). Isolated mitochondria 
usually occur in one of two morphologic states, condensed or orthodox. The first one is 
characterized by contracted, very dense matrix and wide cristae. In the second state matrix 
is expanded and cristae compartments are more compact. Osmotic and metabolic changes in 
mitochondria are responsible for these alterations. It is believed that mitochondrial inner 
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membrane topology is regulated by the cell to improve mitochondria capacity in their 
response to stimuli (Mannella, 2008). 
Tissue cells contain from a few dozen to several thousands of mitochondria and their 
number is associated with cell energy demands. Organs such as heart, muscles or brain 
contain the largest number of mitochondria. Mitochondria are very dynamic structures, 
which can divide, undergo fusion and can take the form of the network of elongated and 
interconnected filaments. The phenomena of fission and fusion have an impact on 
mitochondrial shape, size and number (Logan, 2006). The division and replication of 
mitochondria is under control of the nucleus and is somehow associated with division and 
replication of nuclear DNA. Replication of mitochondria requires coordination between the 
process of mtDNA replication and synthesis of proteins encoded in both genomes (nucleus 
and mitochondrial). The production of both types of proteins must be synchronized to 
preserve their functionality.  
3.2 Electron transport chain and ATP synthesis  
Mitochondrial ATP production involves three main steps: a) the enzymatic “combustion” of 
acetyl in tricarbolxylic acid cycle (TCA), b) the electron transport chain activity and c) ATP 
synthase action. Energy released during this cycle is used to reduce the electron carriers 
NAD+ to NADH and FAD2+ to FADH (Duchen, 2004). Electrons from NADH and FADH2 
are transferred to the respiratory chain - a coupled enzyme systems composed of four 
complexes (Complex I - IV). Complex I (NADH dehydrogenase) is the major entrance point 
of electrons to respiratory chain and is composed of two domains. One domain, localized in 
withe membrane, is involved in proton translocation across the bilayer, and the other, 
matrix-exposed domain, is responsible for oxidation of NADH. FADH2 is the donor of 
electrons to succinate dehydrogenase (Complex II) which is the second entrance point of 
electrons to the ETC. Electrons from both complexes are transferred on mobile intermediate 
– ubiquinone, which is converted to reduced form - ubiquinol. The flow of electrons from 
ubiquinol is directed through the Complex III, also known as ubiquinol-cytochrome c 
reductase, to another carrier - cytochrome c, which transfers electrons to Complex IV - 
cytochrome c oxidase. Finally, at the very end of the respiratory chain, Complex IV reduces 
the oxygen to water in sequential four-electron transfer (Adam-Vizi & Chinopoulos, 2006). 
The oxidation of NADH and FADH2 provides the energy to transport protons from 
mitochondrial matrix into the intermembrane space by the proton pumps (Complexes I, III, 
IV). The difference in the proton concentration, and thus the difference in the electric charge 
across the inner mitochondrial membrane creates the electrochemical potential gradient, 
also called an electrochemical proton gradient or a ’proton-motive force’, which is mainly 
expressed as a mitochondrial transmembrane potential (Nazaret, 2008). The structure of 
mitochondrial electron transport and the scheme showing ATP production by mitochondria 
was introduced in Fig. 4. 
Energy needed to phosphorylate ADP by ATP synthase comes from the entry of protons 
back into the matrix through the proton channel of this complex. This process is called 
oxidative phosphorylation (Frey & Mannella, 2000). ATP is then transported to the 
cytoplasm by the adenine nucleotide translocase (ANT). However, there are several 
mechanisms that may lead to the loss of mitochondrial potential, including an inhibition of 
respiration, failure in substrate supply and uncoupling mechanisms that cause proton leak 
across the membrane. 
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Fig. 4. The general mechanism leading to oxidative phosphorylation is as follows: high-
energy electrons (marked as e-) derived from NADH and FADH2, are moving along the 
respiratory chain composed of four protein complexes (Complex I - IV) and two additional 
electrons carriers: ubiquinone (coenzyme Q, Q), a small molecule freely moving in the inner 
mitochondrial membrane layer, and cytochrome c (Cyt c), localized in the intermembrane 
space attached to the inner membrane. Part of the energy released in this process is used up 
in the action of proton pumps transporting protons (H+) from matrix to the intermembrane 
space. Across the inner membrane electrochemical gradient of protons is formed. Protons 
tend to return to the mitochondrial matrix and restore alignment of H+ concentration on 
both sides of the membrane. When they pass back through transmembrane protein complex 
– ATP synthase - the energy of their movement is used for the synthesis of ATP from ADP 
and inorganic phosphate (Pi).  
3.3 Free radical generation by mitochondria  
Oxidative metabolism and ATP synthesis are closely associated with ROS generation in 
mitochondria. These organelles consume 80–90% of cell's oxygen during oxidative 
phosphorylation. The electron transport chain is the main source of ROS in functioning 
mitochondria. Approximately 0.2–2% of the oxygen taken up by a cell is converted by 
mitochondria to ROS. Superoxide (O2−) is the main product of these transformations, and it 
is then converted to hydrogen peroxide (H2O2) by spontaneous dismutation or by 
superoxide dismutase (SOD). Glutathione peroxidase or catalase, in turn, convert hydrogen 
peroxide into water. If this change does not occur, in the presence of divalent cations H2O2 
can undergo Fenton's reaction to produce even more harmful hydroxyl radical (OH). 
Oxygen can be reduced to superoxide in one-electron step, theoretically, at each step of the 
respiratory chain, but in reality two major sites of superoxide generation are Complex I and 
Complex III (Paradies et al., 2010, as cited in Murphy, 2009). There is a considerable 
experimental support for two mechanisms of ROS production by complex I. The first one is 
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the production of ROS as a consequence of so-called reverse electron transfer (RET) in the 
mitochondrial respiratory chain. RET is a set of redox reactions in the mitochondrial ETC 
that allows electrons to flow from coenzyme Q to NAD+ instead to oxygen. The other one 
takes place under normal conditions, whereas most of the energy from the creation of 
mitochondrial potential difference is used to generate ATP through ATP synthase. This 
process causes collapse of the proton gradient. The amplitude of the electrochemical proton 
gradient regulates the flow of electrons through the ETC. When the electrochemical 
potential gradient is high, for instance under conditions of high glucose concentrations, the 
life of electron transport intermediates that are involved in superoxide formation, such as 
ubisemiquinone, is prolonged. The reason of such condition is that the activities of of ETC 
proton pumps depend on the proton gradient across the inner membrane and the 
membrane itself – two components of proton-motive force (Duchen, 2004).  
3.4 Free radical targets and the oxidative vicious circle  
Mitochondria are continuously exposed to action of reactive oxygen species so they need to 
have a system that will prevent them against destructive effect of oxidative damage. In fact, 
mitochondria are equipped in complicated multi-leveled ROS defense network consisting of 
enzymes and non-enzymatic antioxidants. They contain a high concentration of glutathione, 
ǂ-tocopherol and manganese-containing superoxide dismutase (MnSOD). The role of 
MnSOD is the dismutation process of superoxide radical to H2O2. The product of MnSOD 
reaction is detoxified by other enzymes, i.e. catalase, which converts H2O2 into O2 and H2O. 
Mitochondria possess also another system capable of efficient superoxide removal - the 
cytochrome c, which is than regenerated (oxidized) by its natural electron acceptor, 
cytochrome c oxidase (Complex IV). In intact mitochondria, superoxide may be efficiently 
scavenged by intramitochondrial antioxidant defences (Duchen, 2004). An imbalance 
between oxidants and antioxidants induces oxidative stress responsible for alteration of 
biomolecules and intracellular signaling pathways present in every cell (Edeas et al., 2010a). 
Mitochondria are a major source of ROS generation, but what is important, they are also its 
major target (Duchen, 2004). Mitochondrial membrane lipids, mainly long-chain 
polyunsaturated fatty acids (PUFAs), are also susceptible to oxidative stress. PUFAs are 
basal components of mitochondrial phospholipids. The sensitivity of PUFAs to oxidation 
increase with the increasing number of double bonds per fatty acid molecule. Peroxidation 
of membrane phospholipids causes alterations in their structure and consequently may 
disrupt organisation of the lipid bilayer. It contributes also to changes in membrane fluidity 
and/or permeability, and causes changes in the mitochondrial membrane potential, in 
respiratory capacity and in oxidative phosphorylation. ROS are also responsible for 
alterations in proteins, which may manifest by changes in their structure, proteolytic 
susceptibility and spontaneous fragmentation. Oxidative damage especially affects the 
mitochondrial electron transport chain and, when the ETC enzymes stop working properly, 
the ROS production increases. This may result in the incomplete oxygen consumption, 
reduced production of ATP, and finally overproduction of ROS (Waldbaum & Patel, 2009).  
4. Mitochondrial physiology in diabetes  
Mitochondria are provided with a variety of bioenergetic functions mandatory for the 
regulation of intracellular energy production. Alteration of bioenergetic activities may have 
drastic consequences on cellular function through the perturbation of energetic charge and 
balance of the cell (Fig. 5). 
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Fig. 5. The overall impact of the burden of hypergycaemia in diabetes on functioning of 
mitochondria.  
Abnormalities of mitochondrial metabolism causing human disease have been recognised 
for more than 40 years. Numerous reports clearly indicate the association between 
mitochondrial dysfunction and diabetes. Nevertheless, some mechanisms of mitochondrial 
role in this pathology still requires further elucidation. Therefore different animal model 
studies are involved in the investigation of explaining these unknown mechanisms. There 
are several models of experimental diabetes that mimic two common types of diabetes. 
Streptozotocin-induced diabetes is a widely accepted animal model for type 1 diabetes, 
resulting from the inability of the pancreatic beta cells to produce insulin. For the research 
on type 2 or the insulin resistant state, resulting from the inefficient use of insulin by the 
tissues to regulate blood glucose concentration, some genetically manipulated animal 
models (e.g. Zucker fatty rats (ZFR), ob/ob (obese) mice, CP (corpulent) rats, GK (Goto-
Kakizaki) rats, Akita mice) may be utilized (Srinivasan & Ramarao, 2007).  
4.1 Mitochondrial dysfunction and diabetes type 1  
Streptozotocin (STZ) is a naturally occurring chemical that is particularly toxic to the insulin-
producing ǃ cells of the pancreas in mammals and is used to generate Type 1 diabetes in the 
experimental model. Animals with diabetes induced by STZ exhibit increased mitochondrial 
oxidative stress and dysfunction. Other agent, alloxan, a toxic glucose analogue, is also used in 
order to generate type 1 of diabetes. Alloxan selectively destroys insulin-producing cells in the 
pancreas when administered to rodents and many other animal species, and has been shown 
to cause also mitochondrial dysfunction. Alloxan-treated severe diabetic rats were shown to 
exhibit impaired mitochondrial phosphorylative activities and low mitochondrial oxidation–
reduction states (Yamamoto et al., 1981). In one month old alloxan-diabetic animals the 
enzyme activity of the mitochondrial membrane marker, F0F1-ATPase, was found to be 
decreased. Insulin treatment caused hyperstimulation of the activity, whereas in late-stage 
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diabetes the catalytic efficiency of the enzyme was increased and became decreased upon 
insulin treatment (Patel & Katyare, 2006). 
Mitochondrial dysfunction in diabetic rats can be succinctly summarized into: decreased 
mitochondrial 3'-AMP forming enzyme activity, increased oxidative and nitrosative stress, 
decreased oxygen consumption, loss in mitochondrial transcriptional capacity, increased 
HMG-CoA synthase, increased levels of pyruvate and dicarboxylate transporters, increased 
degradation of ATPase, changes in phospholipid composition, increased pyruvate 
carboxylase activity, increased fatty acid beta oxidation and ultrastructure alterations.  
4.2 Mitochondrial dysfunction and diabetes type 2  
Type 2 diabetes is the most common metabolic disease in the world, and its prevalence 
much exceeds the prevalence of type 1 diabetes. Among different causes leading to diabetes 
the role of mitochondria is considered substantial. Disorders of the mitochondrial electron 
transport chain, overproduction of ROS and lipoperoxides or impairments in antioxidant 
defenses are encountered in type 2 diabetes. Increased ROS levels lead to generalized 
oxidative damage to all mitochondrial components. Moreover, it is well established that 
mitochondrial function is required for normal glucose-stimulated insulin secretion from 
pancreatic ǃ cells. However, the studies in humans suggest that more subtle defects in 
mitochondrial function may also play a role in the pathogenesis of insulin resistance and 
type 2 diabetes (Fig. 6) (Luft, 1994). 
 
 
Fig. 6. Relationships among hyperglycaemia, mitochondrial damage, oxidative burst and 
diabetic complications. 
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Some data support the hypothesis that insulin resistance in humans arises from defects in 
mitochondrial fatty acid oxidation, which in turn leads to increased intracellular fatty acid 
metabolites that disrupt insulin signaling (Petersen et al., 2003). Alternatively, the reduction 
in mitochondrial oxidative phosphorylation activity in insulin-resistant individuals could be 
due not to mitochondrial loss, but rather to a defect in mitochondrial function. This 
hypothesis is supported by muscle biopsy studies. In one such study, the activity of 
mitochondrial oxidative enzymes was found to be lower in type 2 diabetic subjects, and in 
another, the activity of mitochondrial rotenone-sensitive nicotinamide adenine dinucleotide 
oxidoreductase [NADH:O(2)] was found to be lower (Lowell & Shulman, 2005).  
4.3 Alterations in cardiac mitochondria observed in diabetes 
Cardiovascular diseases are the predominant cause of death in patients with diabetes 
mellitus. Underlying mechanism for the susceptibility of diabetic patients to cardiovascular 
diseases still remains unclear. Elevated oxidative stress was detected in diabetic patients and 
in animal models of diabetes. Hyperglycaemia, oxidatively modified atherogenic 
lipoproteins, and advanced glycation end products act in a concerted action together with 
oxidative stress, and cumulatively contribute to progression of late diabetic complications. 
Mitochondrial dysfunction increases electron leak and the generation of ROS from the 
mitochondrial respiratory chain (MRC). High levels of glucose and lipids impair the 
activities of MRC complex enzymes. Furthermore, increased activity of NADPH oxidase 
(NOX), which generates superoxide from NADPH in cells, was detected in diabetic patients 
(Shen, 2010). 
Because mitochondria constitute 20–30% of the cardiac myocytes, one of the potent causes 
for heart malfunctioning in diabetes is the impaired mitochondrial function and 
consequently the decreased ATP generation (Rolo & Palmeira 2006).  
Many reports evidenced that diabetic hearts show impaired mitochondrial function, 
decreased ATP generation, decreased oxidative capacity, increased ROS, abnormal 
morphology, increased UCP-3 level, decreased mitochondrial calcium uptake and increased 
susceptibility to MPT induction (Fig. 5).  
Distortions in cardiac mitochondrial bioenergetics are known to occur in both human 
types of diabetes and in models of diabetes in animals. Reduced mitochondrial calcium 
uptake was observed in heart mitochondria from STZ-treated rats. This was related to 
enhanced susceptibility to MPT induction rather than damage to the calcium uptake 
machinery. Interestingly, heart mitochondria from GK rats were less susceptible to the 
induction of MPT, showing larger calcium accumulation before the overall loss of 
mitochondrial impermeability. Different approaches of antioxidant administration in GK 
rats (vitamin E or coenzyme Q10) showed no success in reversing the diabetic phenotype 
(Oliveira et al., 2003).  
Diabetic heart failure may be causally associated with alterations in cardiac energy 
metabolism. Fuel selection and capacity for ATP production in the normal and failing heart 
are dictated by several metabolic regulatory events at the level of gene expression. Decline 
in the capacity for ATP, as caused by progressive impairment of mitochondrial function, is a 
gradual step in the progression to heart failure of any cause. Fetal heart depends on glucose 
and the adult heart on glucose and fatty acids. The switch between fatty acid oxidation and 
glucose in the adult heart leads to a healthy metabolic situation (Huss & Kelly, 2005). In the 
insulin-resistant and diabetic heart, fatty acid oxidation is increased and glucose utilisation 
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is diminished. Long-term consequence of fatty acid oxidation is mitochondrial dysfunction. 
A number of mechanisms may be responsible for enhanced fatty acid utilisation in type 2 
diabetic hearts, such as increased fatty acid uptake into the cell and mitochondria, increased 
UCP-3 expression, and stimulation of peroxisome proliferator-activated receptor-ǂ (PPARǂ) 
(Fig. 7) (Rolo & Palmeira, 2006). 
 
 
Fig. 7. The role of cardiac mitochondria in the development of heart failure in a course of 
diabetes. 
Diabetes-associated metabolic disorders may cause the mitochondrial dysfuntion and 
upregulation of NOX in the cardiovascular system, which lead to increased ROS production 
and oxidative stress in vasculature and blood circulation. ROS may directly oxidize or 
indirectly regulate molecules related to atherosclerosis and thrombosis. Mitochondrial NOX, 
or its regulators may be considered as potential drug targets for the prevention and/or 
treatment of diabetic cardiovascular complications. 
5. Therapeutic approaches to reduce diabetic complications  
Patients with diabetes mellitus are usually treated with a combination of pharmacological 
agents and habitual approach, i.e. their lifestyle modification. The development of new 
antidiabetic agents, such as insulin analogs and incretin-based therapies, has led to 
treatment strategies that enable numerous patients with diabetes to improve their lifestyles.  
5.1 Use of insulin in a common diabetes therapy – its advantages and disadvantages  
Type 1 diabetes mellitus is underlied by the shortage of insulin, which plays a crucial role of 
carbohydrate and fat metabolism. Its absence causes rather a complex array of serious 
impairments in patients’ health, e.g. hiperglycaemia, ketoacidosis, coma and even death. 
Hence, the injection of exogenous insulin to diabetic individual is essential to: (a) maintain a 
normal glucose concentration and (b) avoid the advanced microvascular complications, such 
as retinopathy, nephropathy or neuropathy.  
Insulin was discovered by Banting and Best and this event was a milestone in the treatment 
of patients with diabetes (Bliss, 1982). Initially, bovine, porcin and even some fish analogues 
were applied to avoid diabetic ketoacidosis. However, gradually the scientists were 
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challenged by the uprising problems in patients injected with animal insulins (mainly 
because of their rather high impurity and immunogenicity) and were forced to develop a 
new class of insulins. Improved techniques used for insulin purification combined with 
other compounds like protamine and zinc, enabled to manufacture protamine insulin with 
the prolonged time of activity and later, the more stable protamine zinc insulin (Hagedorn 
et al., 1936). Moreover, further scientific discoveries shed light on better understanding of 
insulin structure and activity and initiated a new avenue to design human insulin analogues 
characterized by the properties of prolonged hormone activity in a bloodstream.  
At present, there are few types of short-acting insulin analogues used in anti-diabetes 
therapy, and among them:  
- insulin lispro (Humalog manufactured by Elli Lilly and Company), which was 
approved and launched into the market in 1996. Its modified amino acid sequence 
provides faster absorption, which is essential to ameliorate postprandial glucose level. 
The studies revealed that the activity peak of lispro appears in 1 hour after using and 
lasts for next 3-4 hours (Howey et al., 1994) 
- insulin glulisine (Apidra manufactured by Sanofi-Aventis), which possesses 
asparagine at position B3 and glycine at position B29 in amino acid chain (Garg et al., 
2005).   
- insulin aspart (NovoRapid manufactured by Novo Nordisk), in which proline is 
replaced with aspartic acid what facilitates its faster absorption (Mudaliar et al., 1999).  
Long-acting insulin analogues are crucial to mimic the endogenous insulin secretion. 
Thereby a specific modification of insulin structure was essential to obtain longer acting 
analogues. There are two approaches leading to diminish absorption: the first one is to 
change the isoelectric point of insulin and the second one is to acetylate a hydrophobic 
residue with fatty acid. 
- insulin glargine (Lantus, Sanofi-Aventis) exemplifies a long-acting insulin analogue, in 
which asparagine is substituted by glycine at position A21 and the position B30 is 
enriched with two molecules of arginine at B31 and B32 (Bolli & Owens, 2000). These 
alterations have an impact on the structure and an isoelectric point of insulin, 
contributing to a decrease in its solubility after injection. Finally, the result of these 
changes is the product, which acts about 20 hours (Heise et al., 2002). 
- insulin detemir (Levemir, Novo Nordisk) is characterized by long acting properties 
(17-20 hours) obtained as a result of acetylation with fatty acid at the position B29 and 
by removal of threonine at B30 (Havelund et al., 2004).  
After long years of experience and observations, nowadays, multiple daily injection 
program is believed to be the most reasonable approach in modern diabetic treatment in 
order to mimic the physiological insulin release. However, it implies that patients have to 
undertake more inconvenient therapy resulting from the scheduled injections of both short- 
and long-acting insulins. To deal with this problem, clinicians and patients may choose an 
alternative method, which requires biphasic insulin analogues administration.  
Patients with pre-diagnosed type 2 diabetes should take seriously into account the radical 
change of their lifestyle in order to cause a delay of possible medical intervention. Under 
conditions when diet or changing a lifestyle may not be sufficient enough, additional 
pharmacological treatment is required to avoid a severe consequence of this disease. 
Nowadays, medicine is focused on delivery a large number of drugs. From pharmacological 
point of view, these compounds should be effective in improving insulin efficiency or 
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effective in enhancing its secretion from pancreas. Among those substances are: 
sulfonylureas, biguanides, thiazolidinediones, meglitinides, ǂ-glucosidase inhibitors, amylin 
analogues, incretin hormone mimetics and dipeptidyl peptidase 4 inhibitors. 
- sulfonylureas belong to the drugs most frequently used in diabetes treatment. It is known 
that these oral hypoglycaemic agents interact with ǃ-cell pancreas cells causing insulin 
secretion, insulin sensitivity amelioration, as well as glucose synthesis reduction. 
However, in order to treat patients using sulfonylureas, an endogenous secretion of 
insulin at the same/similar level and a balanced diet are required (Gerich, 1989) 
- metformin, representing a class of biguanides, is a commonly used oral hypoglycemic 
agent for the treatment of type 2 diabetes. Metformin is also known as an inhibitor of 
high glucose- or AGEs-induced ROS generation (Bellin et al., 2006) 
- thiazolidinediones (glitazones, TZD), oral anti-diabetic drugs, are based on the 
improving of adipose tissue and muscle sensitivity to insulin treatment (Day, 1999). 
However, troglitazone, one of the class of thiazolidinediones, was taken off the market 
since the hepatotocity has been noticed (Watkins & Whitcomb, 1998).  
Development of the obesity associated with diabetes requires using a novel combination 
treatment, which aims at retarding the microvascular and macrovascular complications 
occurring in diabetes and obesity. Therefore, some anti-diabetic agents have been indicated to 
maintain an adequate glucose level in an organism suffering from diabetes. The number of 
anti-diabetic drugs delivered by subcutaneous injection increases constantly and to date there 
are numerous agents already launched into market, as well as others, tested in the clinical 
trials (Fig. 8).  
- glucagon-like-peptide-1 agonist (GLP-1), one of the first among subcutaneous drugs 
used in medicine. Its beneficial effect was achieved by suppression of glucagon 
secretion and weight loss. Unfortunately, it soon appeared that in the organism GLP-1 
was active only 2 min. It was the main reason why scientists started to work on 
improved GLP-1 analogues. 
- exenatide and liraglutide were introduced into market in the year 2005 and 2009, 
respectively, as novel GLP-1 analogues. Each of them decreases HbA1c level and 
provides the weight loss. The main difference between these agents is their half-lives in 
a circulation. Exenatide yields therapeutic effect in 4-6 hours, whereas half-life of 
liraglutide was enhanced to 12-15 hours (Gentilella et al., 2009).  
- bromocriptin belongs to drugs used in the treatment of Parkinson disease. However, 
recently it has been shown that this therapeutic agent ameliorates insulin sensitivity, 
leading to enhancing glucose control and lowering the incidence of hypoglycaemia (Pijl 
et al., 2000). Although bromocriptin provides weight loss and diminishes concentration 
of plasma triglyceride and free fatty acids, it was evidenced that after using 
bromocriptin the patients suffer from several side effects, like nausea, hypotension and 
psychiatric disturbances.  
Diabetes mellitus has been associated with the increased mortality risk due to non-diabetic 
factors, like several types of solid tumours, including the cancers of colon, breast and 
pancreas. Similar associations have been noted for central obesity and other conditions 
associated with increased levels of circulating insulin. These observations have given rise to 
the hypothesis that growth of these tumours, which are characterised by abnormal 
expression and function of the insulin–IGF-1 series of receptors, may be promoted by the 
trophic action of insulin interacting with these receptors. The cancer risk associated with 
diabetes may also be influenced by therapy in a given diabetic individual: for example, the 
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risk of colon cancer is higher in individuals on insulin, patients on metformin are less likely 
to be diagnosed with cancer, and the risk of mortality from solid tumours is lower for 
metformin than for exogenous insulin or sulfonylureas. As a recognition dawns that cancer 
should be numbered among the complications of diabetes, the possibility that therapies for 
diabetes may influence tumour progression is likely to attract the increasing interest and 
concern. Furthermore, the observation that both endogenous insulin and exogenous insulin 
therapy are associated with tumour progression raises the questions as to the safety of the 
insulin analogues, which have subtly modified receptor binding properties and may 
accelerate the growth and proliferation of both healthy and tumour cell lines in culture. 
 
 
Fig. 8. Sites of action of major oral therapeutical agents used in the treatment of type 2 
diabetes. Pharmacological therapies aimed at: inhibiting carbohydrate breakdown in the gut 
(α-glucosidase inhibitors), stimulating insulin secretion (sulfonylureas, repaglinide, 
nateglinide), suppressing hepatic gluconeogenesis (thiazolidinediones, biguanide), or 
accelerating skeletal muscle glucose metabolism (thiazolidinediones, biguanide) exhibit 
beneficial effects on fasting and/or postprandial plasma glucose, and consequently concord 
overall metabolic control in type 2 diabetic patients. Thus, a need for concerted combination 
therapy to successfully control a burden of hyperglycaemia in a majority of DM2 patients 
becomes a growing expectation by physicians and other health caregivers. 
5.2 New agents – new hopes and new perspectives 
The growing number of people with diabetes still requires novel combined treatments 
aimed at retardation of microvascular and macrovascular complications in the future. 
Therefore, anti-diabetic complications agents are sought to maintain an adequate glucose 
level in an organism. The number of anti-hyperglycaemic drugs delivered by subcutaneous 
injection increases constantly and to date there are numerous agents launched into market 
and examined in clinical trials. However, no such compounds/drugs that could be 
successfully applied in the treatment of diabetes have emerged hitherto, as the validated 
outcomes of clinical trials. Intensive studies are continued in order to develop a modern 
formula for effective amelioration of a burden associated with diabetes and late diabetic 
complications in diabetic patients in the future. 
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Studies on the formation of AGEs have been conducted with the goal to find promising 
pharmacological agents used in prevention or curing diabetic complications. The main 
target for these agents is to retard the formation of AGEs or to brake the AGE cross-links 
formed during Maillard reaction. 
In order to prevent the AGEs formation the following therapeutic inhibitors have been 
developed and studied: 
- pyridoxamine (PM), a form of vitamin B6, is thought to inhibit AGEs structures by 
capturing redox metal ions (Voziyan et al., 2003). In order to examine the anti-diabetic 
properties of PM under in vivo conditions, the model of diabetes mellitus induced by 
streptozotocin (STZ) was applied. The results of PM administration demonstrated the 
reduction in hyperglycaemia level and improvement in the plasma lactate/puryvate 
ratio. The decreased amounts of AGEs have also been noted (Degenhard et al., 2002). 
Moreover, it was also revealed that PM can act as inhibitor of protenuria and 
hyperlipidaemia in diabetes mellitus type 1 (Voziyan, 2005).  
- benfotiamine is a derivative of vitamin B1, which is involved in a limitation of 
methylglyoxal formation and lowering of AGEs accumulation (Gadau et al., 2006). 
- ALT-711 is a new stable analogue of N-phenal thiazolinium bromide (PTB). Its 
mechanism of action is based on preventing metal-catalyzed glycation (Price et al., 2001).  
- Acetylsalicylic acid (Aspirin®), salicylates and ibuprofen possess an anti-
inflammatory properties, which are important in the decreasing of the risk of cataract in 
people suffering from diabetes. As a radical scavengers, they may reduce the level of 
free radicals and/or chelate metal ions (Dinis et al., 1994). 
- chromium deficiency is associated with the blood sugar irregularities of diabetes. 
Recent studies have demonstrated that chromium is effective in treating various types 
of diabetes, including types 1 and 2, gestational, and steroid-induced diabetes. 
Treatment of type 2 diabetes with chromium has led to improvement in blood glucose, 
insulin, and haemoglobin A1c (HbA1c) levels. The use of organic chromium complexes 
has been found to give superior results when compared to inorganic salts. Chromium 
has been found to be effective in reversing diabetes caused by the therapeutic use of 
glucocorticoids. Chromium picolinate (600 μg/day) was effective in lowering blood 
glucose almost twice (from 13.9 mM/L to 8.3 mM/L) in 47 of 50 patients. This therapy 
in patients was also able to reduce the doses of insulin and/or hypoglycaemic 
medications by half within one week from the beginning of chromium supplementation 
(Lamson & Plaza, 2002) 
Among the newest agents tested in both in vitro and in vivo studies are poly(amido)amine 
PAMAM dendrimers and ǃ-resorcylidene aminoguanidine (RAG), a derivative of 
aminoguanodine. 
- PAMAM dendrimers are widely studied all over the world in almost every field of 
science. Their unique structure with nucleophilic character provided by surface amino 
groups may play an important role in the prevention or amelioration of 
hyperglycaemia. The ability of conjugation of PAMAM dendrimers to certain 
biologically relevant molecules makes them promising agents for using in biomedicine 
area, either as drugs or drug delivery systems. Experimental in vitro studies revealed 
that dendrimers appear very effective in scavenging glucose and reducing protein 
glycation (Fig. 9) (Labieniec & Watala, 2010). It was also evidenced that PAMAM 
dendrimer G4 administrated to rats with streptozotocin-diabetes acted as glucose 
scavenger and suppressed the accumulation of AGEs products, as well as some other 
markers of oxidative and carbonyl stress (Labieniec et al., 2008).  
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- aminoguanidine was the most promising oral antihyperglicaemic agent based on 
antioxidant capability and reduction of carbonyl reactive intermediates (Brownlee et al., 
1986). Nevertheless, the B6 vitamin depletion and oxidative stress production after 
using of aminoguanidine by patients with diabetes has been recorded, and therefore 
this compound was removed from clinical trials. Since then, new analogues of 
aminoguadine were synthesized in order to avoid the undesirable side effects of 
aminoguanidine itself. β-resorcylidene aminoguanidine (RAG) is one of these 
analogues, which seems to be the most promising and effective antioxidative and anti-
diabetic agent amongst the others tested hitherto. The majority of studies have 
demonstrated that RAG is able to limit diabetes-associated long-term complications 
(protein glycation, AGEs formation, ROS level). Scientists suggest that RAG acts not 
only as antioxidative and/or anti-diabetic agent (Waczulíková et al., 2000, Vojtaśśak et 
al., 2008), but has also been shown to act as antithrombotic compound, independently 
of its anti-glycation activities (Watala et al., 2009).  
 
 
Fig. 9. The proposed mechanism of anti-glycation action of poly(amido)amine dndrimers 
(PAMAM). 
Under conditions of excessive glucose the model protein (bovine serum albumin, BSA) 
undergoes extensive glycation (A), which becomes retarded and reduced to a large extent in 
the presence of poly(amido)amine dndrimers, generation 4.0 (PAMAM G4.0). 
6. Conclusion 
Diabetes is not merely a disease of impaired insulin sensitivity or insulin release, but may be 
a global metabolic dysfunction, including, among others, the collapse of the mitochondrial 
energy system. The role of the mitochondria in the metabolism associated with the 
pathophysiology of diabetes seems unique, mainly because a generation of ROS (which 
seem a natural part of mitochondrial physiology) constitutes a major treat in the 
development of diabetic sequelae. ROS play the central role in mediating various metabolic 
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defects associated with the diabetic state. Therefore, inhibition of ROS production and/or 
enhancement of ROS scavenging will prove to be beneficial therapies. Hyperglycaemia 
elicits an increased ROS production, presumably from the mitochondrial respiratory chain. 
An important challenge for future research is to determine whether strategies aimed to 
improving mitochondrial functionality by using agents with anti-diabetic properties might 
have therapeutic potential in the treatment of diabetes. On the other hand, the better 
understanding of mitochondrial biology is still needed to facilitate the judicious selection 
and development of compounds/agents, which could be used as “mitochondrial drugs”. 
Further studies are certainly required to better understand how these novel compounds and 
mitochondria may interact with each other, and how our understanding of such interaction 
might be utilized for the impaired mitochondrial functioning in the presence of diabetes. 
These investigations should also determine, which genetic, environmental, pharmacological 
and nutritional factors are possibly involved in an individual patient’s susceptibility and, 
which treatments can be used safely in those patients, who suffer from heavy diabetes and 
are crushed by the burden of advanced long-term complications. 
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